hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06285019 id: GWK-2023-004 briefTitle: Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular Carcinoma overallStatus: RECRUITING date: 2023-12-01 date: 2024-12-31 date: 2025-12-31 date: 2024-02-29 date: 2024-02-29 name: Fudan University class: OTHER briefSummary: This is a single-center, single-arm, phase II clinical study, to explore the efficacy and safety of modified TOMOX-HAIC combined with sintilimab and bevacizumab biosimilar as first line treatment in patients with advanced hepatocellular carcinoma. conditions: Hepatocellular Carcinoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 65 type: ESTIMATED name: TOMOX-HAIC name: Sintilimab name: Bevacizumab measure: objective response rate (ORR) measure: disease control rate (DCR) measure: Progression-Free Survival (PFS) measure: Time to progression (TTP) measure: Duration of response (DOR) measure: overall survival (OS) measure: adverse event (AE) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fudan University Shanghai Cancer Center status: RECRUITING city: Shanghai state: Shanghai zip: 200062 country: China name: Lu Wang, M.D. role: CONTACT phone: +86-18121299357 email: w.lr@hotmail.com lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06285006 id: MScAZASTPED025/23/202/12/2021 briefTitle: Desmopressin Monotherapy for Monosymptomatic Nocturnal Enuresis overallStatus: RECRUITING date: 2024-02-23 date: 2024-05-01 date: 2024-05-12 date: 2024-02-29 date: 2024-04-23 name: Al-Azhar University class: OTHER briefSummary: Nocturnal Enuresis (NE) is defined as the involuntary passage of urine during sleep past the age of usual control, which is considered a developmental age of 5 to 7 years.
NE is a common problem that causes distress to both children and their families. It has an adverse impact on behavior and social life, affects self-esteem, and can result in poor emotional well-being. In Egypt, the prevalence of NE in primary school children is about 15.4%. The family history was seen to have had a markedly significant impact on the occurrence of NE in the studied children. The mainstay of treatment is urotherapy with information and psychoeducation about normal lower urinary tract function, the underlying cause of MNE, disturbed bladder dysfunction in the child with NMNE, and instructions about therapeutic strategies. Alarm therapy and desmopressin are effective in randomized trials. Children with NMNE first need treatment of the underlying daytime functional bladder problem before treatment of nocturnal enuresis. conditions: Nocturnal Enuresis studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 50 type: ESTIMATED name: Desmopressin measure: The number of episodes per week after desmopressin treatment sex: ALL minimumAge: 7 Years maximumAge: 14 Years stdAges: CHILD facility: Alazhar university status: RECRUITING city: Assiut zip: 11884 country: Egypt name: Omnia Nassar, Dr role: CONTACT phone: 01010112054 email: omnianassar835@gmail.com name: Hosny Elmasry, Prof role: CONTACT phone: 01010112054 email: omnianassar835@gmail.com lat: 27.18096 lon: 31.18368 hasResults: False
nctId: NCT06284993 id: 2023-214-KY briefTitle: Acupuncture of Different Treatment Frequency in Chronic Plantar Fasciitis overallStatus: RECRUITING date: 2024-02-20 date: 2026-09-30 date: 2026-12-30 date: 2024-02-29 date: 2024-02-29 name: Guang'anmen Hospital of China Academy of Chinese Medical Sciences class: OTHER briefSummary: Plantar fasciitis (PF) is one of the most common causes of heel pain, typically characterized by a sharp pain in the plantar aponeurosis, specifically near the insertion site close to the medial process of the calcaneal tuberosity. It has been reported that 1 in 10 people are expected to be affected by PF in their lifetime. A comprehensive internet-panel survey conducted among the adult United States population revealed the population-based prevalence of self-reported PF with pain in the last month was 0.85 percent. Approximately 1 million patients are diagnosed with this disease each year in the United States. PF was believed to be an acute inflammatory disease, but patient samples show it is actually a chronic degenerative process caused by various factors such as repetitive stresses, vascular and metabolic disorders, excess free radicals, high temperatures, genetic factors, and conditions like rheumatoid arthritis and spondyloarthropathies. PF may be associated with impaired health-related quality of life, including reduced life functioning, poor perceived health status and social isolation. Additionally, a recent study indicates that the annual cost associated with PF is $284 million.
The first-line treatments recommended by guidelines for PF encompass physical therapy (including manual therapy, stretching, and others), pharmacological therapy (involving corticosteroids or platelet-rich plasma), and surgical treatment. However, the definite effects of physical therapy still require confirmation. Pharmacological treatments, such as local corticosteroid injections, exhibit a short maintenance period. Some studies indicate that the relief provided by corticosteroid injections lasts up to one month, yet its efficacy diminishes after 6 months. Surgical treatment is generally advised 6 to 12 months after unsuccessful conservative treatment, albeit with the drawback of higher costs, post-surgery recovery time, and patient apprehension.
Acupuncture is one of the most common complementary alternative therapy for the treatment of pain-related diseases such as musculoskeletal muscle, and recent guidelines recommend dry needling as a treatment for relief of plantar fasciitis, with a level of evidence of B. Dry acupuncture is different from acupuncture in terms of theoretical basis, therapeutic apparatus, technical operation and scope of indications, however, the American Alliance for Professional Acupuncture Safety also believes that dry needling falls under the umbrella of acupuncture, but under a different name. In addition, there are systematic evaluations that suggest acupuncture can be a safe and effective treatment for PF, and most of the trials in the systematic evaluations used 4-week treatment courses. Our prior study demonstrated that a 4-week intervention of both electroacupuncture and manual acupuncture resulted in improved pain outcomes among patients with PF.
The frequency of acupuncture stands as a crucial factor influencing its efficacy. A study revealed that needling trials with negative results had a significantly lower frequency compared to those yielding positive results. Furthermore, several studies indicate that acupuncture once a week can be help in conditions such as simple obesity, functional dyspepsia, and overactive bladder in women. There is no universally accepted standard of frequency of treatment for many conditions, including PF. In China, patients with chronic diseases usually receive 3-5 acupuncture treatments per week. However, in most previous trials, individuals with chronic diseases received 1-2 needling sessions per week. An increase in the frequency of acupuncture means an increase in the pain, time, and financial investment associated with the acupuncture process. Therefore, it is critical to optimize the frequency of acupuncture to ensure the effectiveness and feasibility of the treatment while avoiding increasing the burden on the patient. Accordingly, we designed the current trial to compare the effects of different acupuncture sessions (1 session per week versus 3 sessions per week) in a randomized controlled trial (RCT) of chronic PF. The hypothesis is that 1 session per week compared with 3 sessions per week of electroacupuncture treatment over a total of 4 weeks of treatment will provide a similar effect on pain relief in chronic PF. conditions: Plantar Fasciitis, Chronic studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: electroacupuncture(more frequent) name: electroacupuncture(less frequent) measure: The response rate measure: The response rate measure: Change from baseline in the VAS score for worst pain intensity during the first steps in the morning measure: Change from baseline in the VAS score for mean pain intensity during the day measure: Change from baseline in the duration of heel pain during the day measure: Change from baseline in heel pressure pain threshold (PPT) measure: Change from baseline in ankle range of motion (AROM) measure: Change from baseline in Foot and Ankle Ability Measure (FAAM) total score and subscale scores measure: Participant global assessment of improvement measure: Participants' expectation towards acupuncture measure: Safety assessment measure: Adherence assessment measure: Number of cases and number of times painkillers and other treatments sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences Guang'anmen Hospital status: RECRUITING city: Beijing country: China name: Jiaxiang Shi role: CONTACT phone: +8618396129770 email: 476605704@qq.com lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06284980 id: 2369 briefTitle: Gestional Trophoblastic Neoplasia Ultrasound Assessment: Titanium Study acronym: TITANIUM overallStatus: RECRUITING date: 2019-01-24 date: 2024-12-30 date: 2025-12-31 date: 2024-02-29 date: 2024-02-29 name: Fondazione Policlinico Universitario Agostino Gemelli IRCCS class: OTHER briefSummary: Gestational trophoblast diseases are characterized by abnormal proliferation of trophoblastic tissue, which can occur consequent to any pregnancy event. Pre-malignant forms (partial hydatiform mola and complete mola) and malignant forms are distinguished, the latter also known as gestational trophoblast neoplasms (invasive hydatiform mola, choriocarcinoma, placental site trophoblastic tumor, and epithelioid trophoblastic tumor).
The identification of ultrasonographic and echofluximetric features typical of malignant forms as well as the identification of ultrasonographic parameters predictive of chemoresistance to single-drug treatments could help improve their management. conditions: Describe Typical Gray Scale/Color Doppler Ultrasound Features of Gestational Trophoblastic Neoplasia at the US Examination conditions: To Assess if There Are Differences at the Baseline US Scan Between Low-risk and High-risk Patients conditions: To Identify Ultrasound Predictors of Resistance to First-line Single Drug Chemotherapy in Low-risk GTN Patients conditions: To Investigate if Machine Learning (ML) Algorithms (Radiomics, Deep Neural Networks (DNN), and Other Machine Learning Algorithms studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 120 type: ESTIMATED measure: typical features of Gestational Trophoblastic Neoplasia measure: differences at the baseline US scan between low-risk and high-risk patients measure: changes characteristics of Gestational Trophoblastic Neoplasia during treatment sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fondazione Policlinico Universitario Agostino Gemelli, IRCCS status: RECRUITING city: Rome zip: 00168 country: Italy name: Floriana Mascilini role: CONTACT phone: 0630156399 email: floriana.mascilini@policlinicogemelli.it lat: 41.89193 lon: 12.51133 hasResults: False
nctId: NCT06284967 id: Vitamin D In Spondylolysis briefTitle: Association Of Serum Vitamin D Level With Isthmic Spondylolysis overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2025-08-01 date: 2025-09-01 date: 2024-02-29 date: 2024-03-08 name: Assiut University class: OTHER briefSummary: The aim of this study is to compare vitamin D level between young adults with isthmic spondylolysis and a matched healthy control group. conditions: Spondylolysis studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 184 type: ESTIMATED measure: Mean serum vitamin D in both groups. measure: Mean serum calcium level sex: ALL minimumAge: 20 Years maximumAge: 45 Years stdAges: ADULT hasResults: False
nctId: NCT06284954 id: ARGX-117-2301 id: 2023-508337-14 type: OTHER domain: CTIS number briefTitle: A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis acronym: empacific overallStatus: NOT_YET_RECRUITING date: 2024-05-10 date: 2025-07-18 date: 2028-01-20 date: 2024-02-29 date: 2024-03-15 name: argenx class: INDUSTRY briefSummary: This study will evaluate the safety and efficacy of empasiprubart compared with placebo in adult participants with dermatomyositis (DM). conditions: Dermatomyositis conditions: Myositis studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: Empasiprubart IV name: Placebo IV measure: Incidence and severity of adverse events (AEs) measure: Percentage of participants discontinuing investigational medicinal product (IMP) due to an adverse event (AE) measure: Mean TIS sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06284941 id: KY 2023-001-001 briefTitle: A Study of Ropivacaine Complex Methylene Blue Fascia Iliaca Compartment Block on Analgesia in Patients Undergoing Hip Arthroplasty overallStatus: ENROLLING_BY_INVITATION date: 2023-06-20 date: 2024-06-20 date: 2024-06-20 date: 2024-02-29 date: 2024-02-29 name: Wang wanxia class: OTHER briefSummary: Total hip arthroplasty is currently the most effective method for treating hip joint lesions and improving quality of life, but postoperative severe pain is not conducive to rapid recovery of patients. In recent years, the widespread application of ultrasound has achieved good clinical results in iliac fascia block for postoperative analgesia in THA. However, the use of high-dose local anesthetics can increase the risk of local anesthetic poisoning, and the single block analgesia time is generally less than 24 hours. Methylene blue, as a long-acting analgesic drug, can block the pain transmission of nerve fibers for a long time, achieving analgesic effects without damaging neurons. This study used ultrasound-guided ropivacaine combined with methylene blue to perform iliac fascia block on patients undergoing total hip replacement, with the aim of prolonging pain relief time, reducing complications, and promoting postoperative recovery on the basis of traditional methods. conditions: Femoral Neck Disease studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 90 type: ESTIMATED name: Ropivacaine combined with methylene blue for iliac fascia block measure: Neutrophil lymphocyte ratio measure: visual analogue scale（VAS） measure: Procalcitonin measure: Hypersensitive C-reactive protein measure: Mean arterial pressure measure: Heart rate measure: Duration of surgery measure: Number of postoperative salvage analgesia measure: Walking distance for the first time getting out of bed measure: The number of activities of getting out of bed 48 hours after surgery sex: ALL minimumAge: 65 Years maximumAge: 85 Years stdAges: OLDER_ADULT facility: Jiangyan District Hospital of traditional Chinese medicine attached to the Nanjing University of Chinese Medicine city: Taizhou state: Jiang Su zip: 225500 country: China lat: 32.49069 lon: 119.90812 hasResults: False
nctId: NCT06284928 id: 20240104-01 briefTitle: Gut Microbiota and New Hypertension acronym: MIPHYP-CROSS overallStatus: COMPLETED date: 2019-12-01 date: 2020-06-01 date: 2020-12-01 date: 2024-02-29 date: 2024-02-29 name: Xinjiang Medical University class: OTHER briefSummary: This study aims to explore the gut microbiota patterns in patients newly diagnosed with hypertension, comparing them to those in non-hypertensive individuals. Utilizing cross-sectional analysis, it seeks to identify specific microbial profiles associated with hypertension, which could provide insights into the disease's pathogenesis and potential new avenues for treatment. The research focuses on analyzing fecal samples collected from both groups, using advanced genomic techniques to assess the diversity and abundance of gut bacteria. This investigation could contribute significantly to our understanding of the role gut microbiota plays in cardiovascular health and disease. conditions: Hypertension conditions: Gut Microbiota studyType: OBSERVATIONAL observationalModel: CASE_CROSSOVER timePerspective: CROSS_SECTIONAL count: 100 type: ACTUAL name: Gut Microbiota Analysis measure: Change in Gut Microbiota Composition sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The First Affiliated Hospital of Xinjiang Medical University city: Ürümqi state: Xinjiang zip: 630000 country: China lat: 43.80096 lon: 87.60046 hasResults: False
nctId: NCT06284915 id: MEQ00089 id: MEQ00089 type: OTHER domain: Sanofi Identifier id: 2023-508177-85 type: REGISTRY domain: CTIS id: U1111-1280-6981 type: REGISTRY domain: ICTRP briefTitle: Study on Immunogenicity and Safety of a Meningococcal ACYW Conjugate Vaccine in Healthy Infants and Toddlers overallStatus: RECRUITING date: 2024-03-19 date: 2025-03-10 date: 2025-03-11 date: 2024-02-29 date: 2024-04-17 name: Sanofi Pasteur, a Sanofi Company class: INDUSTRY briefSummary: This study is conducted to support a 2-dose series (1+1 vaccination schedule) for immunization of individuals from 6 months of age. The study is designed to evaluate the non-inferiority of the immunological response of MenACYW conjugate vaccine to Nimenrix® after the completion of the 2-dose series (1+1 vaccination schedule), with the first dose (priming dose) being given at 6-7 months of age to MenACWY- naïve healthy infants and the second dose (booster dose) given at 12-13 months of age. This study will also describe additional immunogenicity parameters and safety of MenACYW conjugate vaccine and Nimenrix® in the same population of participants. conditions: Meningococcal Immunisation conditions: Healthy Volunteers studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: TRIPLE maskingDescription: The study will be performed in a modified double-blind fashion:
nctId: NCT06284902 id: BDR17987 briefTitle: Bioavailability Study of Fexofenadine HCl New Formulation Tablet overallStatus: RECRUITING date: 2024-02-23 date: 2024-05-08 date: 2024-05-23 date: 2024-02-29 date: 2024-03-21 name: Opella Healthcare Group SAS, a Sanofi Company class: INDUSTRY briefSummary: The purpose of the study is to assess the relative bioavailability of a new galenic form of fexofenadine HCl new formulation tablet (test drug) taken with or without water compared to fexofenadine HCl film-coated tablets (reference form) taken with water under fasting conditions. conditions: Healthy Volunteers studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: NONE count: 25 type: ESTIMATED name: Fexofenadine HCl Coated tablet name: Fexofenadine HCl New Formulation Tablet measure: Area Under the Concentration-time Curve From Time Zero Until the Last Observed Concentration (AUC0-t) of Fexofenadine measure: Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated) (AUC0-inf) of Fexofenadine measure: Maximal Observed Concentration (Cmax) of Fexofenadine measure: Time When the Maximal Concentration is Observed (Tmax) of Fexofenadine measure: Time of Observation Prior to the First Observation with a Measurable (non-zero) Concentration (Tlag) of Fexofenadine measure: Terminal Half-life Associated with the Terminal Slope (T1/2z) of Fexofenadine measure: Terminal Elimination Rate Constant (Kel) of Fexofenadine measure: Percentage of Participants with Treatment Emergent Adverse Events (TEAEs) sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: Syneos Health Clinic inc. status: RECRUITING city: Quebec zip: G1P 0A2 country: Canada lat: 46.81228 lon: -71.21454 hasResults: False
nctId: NCT06284889 id: DepActive briefTitle: Behavioral Activation for the Treatment of Depression in Older Adults acronym: DepActive overallStatus: NOT_YET_RECRUITING date: 2024-03-04 date: 2027-12-31 date: 2028-12-31 date: 2024-02-29 date: 2024-02-29 name: Uppsala University class: OTHER name: Västmanland County Council, Sweden name: Sormland County Council, Sweden name: Uppsala County Council, Sweden briefSummary: Depression affects between 5-15% of adults ≥ 65 years in Sweden. Depression in older adults reduces functional ability and quality of life, and increases the risk for morbidity, loneliness, and suicide. Psychological treatment is recommended as a first-line treatment for depression, which about 3% of older adults with depression in Sweden report receiving. One effective psychological treatment is behavioral activation, which reduces depressive symptoms by increasing enjoyable, meaningful and important activities, for example exercise and social activities. The research group conducted a pilot study of telephone based behavioral activation for isolated older adults with depression during the COVID-19 pandemic. The intervention consisted of four telephone calls, and the results showed a significant decrease in depressive symptoms, with maintained effects for six months.
250 individuals will participate in the study. Half of the participants will be randomised to start the intervention immediately, while the other half of the participants will be randomized to a control group receiving treatment as usual at their respective primary care center. Participants will be asked to fill in questionnaires before, after treatment. Questionnaires will also be sent 3- and 6 months after treatment to follow up on the results. Patients will be asked to wear an accelerometer for 5-7 days to record their activity level at baseline, post-intervention and after 3-months. A smaller group of participants (10-15) will be asked to participate in a more detailed interview about how they experienced the treatment. conditions: Depression studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomised controlled multi-center trial primaryPurpose: TREATMENT masking: NONE count: 250 type: ESTIMATED name: Behavioural activation name: Treatment as usual (TAU) measure: Change from baseline in depressive symptoms using the Montgomery-Asberg Depression Rating Scale, MADRS-S measure: Change from baseline in depression diagnosis assessed using the Mini International Neuropsychiatric Interview, MINI measure: Change from baseline in Physical Activity level measure: Change from baseline in anxiety symptoms using the Geriatric Anxiety Scale - 10 item (GAS-10) is a self-rating scale designed to capture anxiety specifically in older adults, with items reflecting affective-, cognitive- and somatic anxiety symptoms. measure: Change from baseline in health and disability using The WHO Disability Assessment Schedule 12-item, WHODAS measure: Change from baseline in self rated quality of life using the EuroQol-5 Dimensions-5 Level Scale, EQ-5D-5L measure: Changes from baseline in Self Efficacy measured with the New General Self-Efficacy Scale, S-GSE. measure: Changes from baseline in loneliness measured with the UCLA Loneliness Scale version 3, UCLA-LS-3. measure: Diagnostic accuracy sex: ALL minimumAge: 65 Years stdAges: OLDER_ADULT facility: Uppsala university city: Uppsala state: Uppland zip: 753 10 country: Sweden name: Mattias Damberg, MD role: CONTACT phone: +46739480910 email: mattias.damberg@pubcare.uu.se lat: 59.85882 lon: 17.63889 hasResults: False